Novartis Received European Approval For Cosentyx As First And Only IL-17A Inhibitor For Hidradenitis Suppurativa
Portfolio Pulse from Charles Gross
Novartis has received European Commission approval for Cosentyx, an IL-17A inhibitor, to be used in adults with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapy.
June 01, 2023 | 8:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis received European approval for Cosentyx, potentially expanding its market and increasing revenues.
The European Commission's approval of Cosentyx for use in adults with hidradenitis suppurativa allows Novartis to expand its market reach and potentially increase revenues. The approval is a positive development for the company and may lead to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100